{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:40Z","timestamp":1779955480426,"version":"3.53.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["003990322"],"award-info":[{"award-number":["003990322"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL141286"],"award-info":[{"award-number":["R01HL141286"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T06:54:59Z","timestamp":1739084099000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world association between ivacaftor initiation and lung function variability: A registry study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0705-715X","authenticated-orcid":false,"given":"Rhonda D.","family":"Szczesniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni-Rosalina","family":"Andrinopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8290-959X","authenticated-orcid":false,"given":"Hancheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Ostrenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-1397","authenticated-orcid":false,"given":"Anushka K.","family":"Palipana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-9293","authenticated-orcid":false,"given":"David J.","family":"Pasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.01.014_bib0001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpeds.2015.08.042","article-title":"Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function","volume":"169","author":"Morgan","year":"2016","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.jcf.2025.01.014_bib0002","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.01.014_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.03.008","article-title":"Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian Cystic Fibrosis Registry","author":"Kawala","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.01.014_bib0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.014_bib0005","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.01.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.02.006","article-title":"Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations","author":"Heltshe","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2025.01.014_bib0007","unstructured":"Team R. RStudio: integrated development for R. Boston, MA: RStudio, PBC; 2020."},{"key":"10.1016\/j.jcf.2025.01.014_bib0008","series-title":"Statistical analysis with missing data","author":"Little RJ R","year":"2002"},{"issue":"5","key":"10.1016\/j.jcf.2025.01.014_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.014_bib0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","article-title":"Year-to-year changes in lung function in individuals with cystic fibrosis","volume":"9","author":"Liou","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.014_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ppul.21526","article-title":"Lung function decline from adolescence to young adulthood in cystic fibrosis","volume":"47","author":"Vandenbranden","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2025.01.014_bib0013","unstructured":"Foundation C.F. Cystic fibrosis foundation patient registry: 2021 annual data report. Bethesda, MD: 2022. (https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf)."},{"issue":"12","key":"10.1016\/j.jcf.2025.01.014_bib0014","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/ppul.23884","article-title":"Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: a longitudinal analysis","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2025.01.014_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.01.014_bib0016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2023.05.004","article-title":"Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis","volume":"22","author":"Rosenfeld","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.202209-829OC","article-title":"Lung function decline in cystic fibrosis: impact of data availability and modeling strategies on clinical interpretations","author":"Szczesniak","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jcf.2025.01.014_bib0018","first-page":"529","article-title":"Longitudinal analysis of FEV1 changes related to antibiotic therapy in children with cystic fibrosis","volume":"100","author":"Javadpour","year":"2007","journal-title":"Ir Med J"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.014_bib0019","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1513\/AnnalsATS.201608-615OC","article-title":"Relationship of antibiotic treatment to recovery after acute FEV(1) decline in children with cystic fibrosis","volume":"14","author":"Morgan","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.01.014_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.014_bib0021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcf.2017.10.003","article-title":"Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation","volume":"17","author":"Wagener","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.01.014_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2021.08.013","article-title":"A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis","volume":"21","author":"Paynter","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.01.014_bib0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1164\/rccm.201607-1373LE","article-title":"Combining clinical trial and patient registry data in Cystic fibrosis: who should Be compared?","volume":"195","author":"Buzzetti","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.01.014_bib0024","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis","volume":"23","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.014_bib0025","article-title":"Estimating the association between blood pressure variability and cardiovascular disease: an application using the ARIC Study","author":"Barrett","year":"2018","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.jcf.2025.01.014_bib0026","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1513\/AnnalsATS.202105-532OC","article-title":"Changes in care during the COVID-19 pandemic for people with Cystic Fibrosis","volume":"19","author":"Sanders","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.01.014_bib0027","first-page":"1","article-title":"Development of elexacaftor - tezacaftor - ivacaftor: highly effective CFTR modulation for the majority of people with Cystic Fibrosis","author":"Middleton","year":"2021","journal-title":"Expert Rev Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:48Z","timestamp":1779953748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325000475"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world association between ivacaftor initiation and lung function variability: A registry study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}